Literature DB >> 30952748

Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy.

Markos Antonopoulos1, Stefaan W VAN Gool2, Dimitra Dionysiou3, Norbert Graf4, Georgios Stamatakos3.   

Abstract

BACKGROUND/AIM: The need for more effective treatment modalities that can improve the clinical outcome of patients with glioblastoma multiforme remains imperative. Dendritic cell vaccination is a fast-developing treatment modality, currently under exploration. Functional immune cell subpopulations may play a role in the final outcome.
MATERIALS AND METHODS: Data from 101 patients drawn from the HGG-2010 trial, including baseline patient characteristics and fluorescence-activated cell sorting of immune cell subpopulations, were analyzed by statistical and machine-learning methods.
RESULTS: The analysis revealed strong correlations between immune profiles and overall survival, when the extent of resection and the vaccination schedule were used as stratification variables.
CONCLUSION: A systematic, in silico workflow detecting strong and statistically significant correlations between overall survival and immune profile-derived quantities obtained at the start of dendritic cell vaccination was devised. The derived correlations could serve as a basis for the identification of prognostic markers discriminating between potential long- and short-term survivors of patients with glioblastoma multiforme. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  GBM; biomarker; circulating lymphocytic phenotype; dendritic cell vaccination; glioblastoma multiforme; immunotherapy; malignant glioma; overall survival

Mesh:

Substances:

Year:  2019        PMID: 30952748     DOI: 10.21873/anticanres.13315

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Palliative Radiotherapy of Primary Glioblastoma.

Authors:  Jaspar Witteler; Steven E Schild; Dirk Rades
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

2.  Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells.

Authors:  David M Peereboom; Tyler J Alban; Matthew M Grabowski; Alvaro G Alvarado; Balint Otvos; Defne Bayik; Gustavo Roversi; Mary McGraw; Pengjing Huang; Alireza M Mohammadi; Harley I Kornblum; Tomas Radivoyevitch; Manmeet S Ahluwalia; Michael A Vogelbaum; Justin D Lathia
Journal:  JCI Insight       Date:  2019-11-14

3.  Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series.

Authors:  Benjamin Gesundheit; Eliel Ben-David; Yehudit Posen; Ronald Ellis; Guido Wollmann; E Marion Schneider; Karl Aigner; Lars Brauns; Thomas Nesselhut; Ingrid Ackva; Christine Weisslein; Arno Thaller
Journal:  Front Oncol       Date:  2020-05-14       Impact factor: 6.244

4.  LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma.

Authors:  Xin He; Jie Sheng; Wei Yu; Kejian Wang; Shujuan Zhu; Qian Liu
Journal:  Cell Mol Neurobiol       Date:  2020-06-11       Impact factor: 5.046

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.